Results 51 to 60 of about 22,701 (163)

Early Diagnosis of Fanconi-Bickel Syndrome and a Novel Mutation inSLC2A2 Gene

open access: yesHaseki Tıp Bülteni, 2019
Fanconi-Bickel syndrome is a metabolic disease caused by mutations in SCL2A2 gene. Hepatic and renal glycogen storage, fasting hypoglycemia, and renal tubular dysfunction are characteristics of the disease that is usually diagnosed at 6-10 months of age.
Ezgi Çelikboya   +4 more
doaj   +1 more source

Diabetes Mellitus ve Obezite Hastalarında Üriner Sistem Enfeksiyonu: Geriye Dönük Değerlendirme

open access: yesDüzce Tıp Fakültesi Dergisi, 2018
Amaç: Bu çalışmada, hastanemiz erişkin ve çocuk endokrin polikliniklerinde diabetes mellitus (DM) ve obezite tanısı almış hastalarda, üriner sistem enfeksiyon etkeni olarak izole edilen patojenlerin dağılımı, bu patojenlerin antimikrobiyallere direnç ...
Özge KILINÇEL   +5 more
doaj   +1 more source

Targeting acute hyperglycaemia in clinical practice [PDF]

open access: yes, 2007
The UKPDS established the benefit of tight glycaemic control in preventing microvascular disease but was unable to demonstrate an effect on cardiovascular disease.
Heller, S.
core   +1 more source

Fasting plasma glucose performs better than glycated hemoglobin and glycated albumin for diagnosing gestational diabetes

open access: yesInternational Journal of Gynecology &Obstetrics, EarlyView.
Abstract Objective Universal screening for gestational diabetes mellitus (GDM) using the oral glucose tolerance test (OGTT) has been recommended. In resource‐poor environments, OGTTs are only administered to high‐risk cases. In countries such as South Africa, where female obesity is common, this translates into high numbers of tests.
Lungile Khambule   +3 more
wiley   +1 more source

Reduced renal sympathetic nerve activity contributes to elevated glycosuria and improved glucose tolerance in hypothalamus-specific Pomc knockout mice

open access: yesMolecular Metabolism, 2017
Objective: Hypothalamic arcuate nucleus-specific pro-opiomelanocortin deficient (ArcPomc−/−) mice exhibit improved glucose tolerance despite massive obesity and insulin resistance.
Kavaljit H. Chhabra   +5 more
doaj   +1 more source

Raised cortisol excretion rate in urine and contamination by topical steroids [PDF]

open access: yes, 2001
No abstract ...
Davies, D.L.   +5 more
core   +1 more source

Effects of glucagon‐like peptide 1 receptor agonists on testicular dysfunction: A systematic review and meta‐analysis

open access: yesAndrology, EarlyView.
Abstract Background Hypogonadism and infertility are two conditions that are heavily affected by overweight and obesity in the male patient. Glucagon‐like peptide 1 agonists (GLP‐1RAs) are a recently introduced class of antidiabetic drugs with powerful weight‐loss effect; this may induce an indirect positive effect on the testicular function ...
Gianmaria Salvio   +6 more
wiley   +1 more source

Importance of screening for glycosuria and proteinuria in antenatal care

open access: yesGomal Journal of Medical Sciences, 2004
Background: The identification and treatment of women with gestational diabetes mellitus continues to be controversial due to the costs involved in the screening and treatment, even in developed countries.
Aziz Marjan Khattak   +5 more
doaj  

Sodium-Glucose Linked Cotransporter-2 Inhibition Does Not Attenuate Disease Progression in the Rat Remnant Kidney Model of Chronic Kidney Disease. [PDF]

open access: yesPLoS ONE, 2016
Pharmacological inhibition of the proximal tubular sodium-glucose linked cotransporter-2 (SGLT2) leads to glycosuria in both diabetic and non-diabetic settings.
Yanling Zhang   +3 more
doaj   +1 more source

Blockade of cannabinoid CB1 receptors potentiates the anti‐fibrotic effects mediated by SGLT2 inhibition in a mouse model of diabetic nephropathy

open access: yesBritish Journal of Pharmacology, EarlyView.
Background and purpose Diabetic nephropathy (DN) is a common complication of diabetes. Current treatments include renin‐angiotensin‐aldosterone system (RAAS) blockers and sodium‐glucose co‐transporter 2 (SGLT2) inhibitors. The cannabinoid CB1 receptor is a potential therapeutic target.
Océane Pointeau   +20 more
wiley   +1 more source

Home - About - Disclaimer - Privacy